Few data are available on pazopanib in patients with renal insufficiency. We investigated the effect of kidney function on treatment outcomes. Kidney function at time of pazopanib initiation does not affect the drug's safety and efficacy. Background: Pazopanib has been approved for first-line treatment of patients with metastatic renal-cell carcinoma on the basis of clinical trials that enrolled only patients with adequate renal function. Few data are available on the safety and efficacy of pazopanib in patients with renal insufficiency. This study investigated the effect of kidney function on treatment outcomes in such patients. Median progression-free survival was 14 months (95% confidence interval [CI], 9.4-18.5) and 17 months (95% CI, 11.4-22.8), and overall survival was 30.5 months (95% CI, 8-53) and 41.4 months (95% CI, 21-62) for group A and group B, respectively, with no significant difference (P ¼ .6). No significant difference between the 2 groups was reported in the incidence of adverse events. Dose reductions were more frequent in group A patients (66% vs. 36%; P ¼ .04). Conclusion: Although the dose of pazopanib was reduced more frequently in patients with renal impairment, kidney function at therapy initiation does not adversely affect the safety and efficacy of pazopanib.
Introduction
Renal-cell carcinoma (RCC) is the third most common malignancy of the urinary tract and accounts for almost 3% of adult malignancies globally, with more than 210,000 new cases and 100,000 deaths annually. 1 Few data exist regarding the incidence of renal dysfunction in metastatic RCC (mRCC) patients; however, this is a patient population at risk for impaired renal function. One small series has estimated the incidence of chronic kidney disease in mRCC to be 37%. 2 Given that patients with mRCC may have several risk factors for impaired renal function (eg, previous nephrectomy, history of chronic kidney disease, arterial hypertension, obesity), it is essential for clinicians to know the efficacy and safety of vascular endothelial growth factoretargeted therapies in the context of compromised renal dysfunction. 2 Systemic therapy with targeted agents, and more recently immune checkpoint inhibitors, is the mainstay of treatment for patients with RCC who experience after surgery or whose disease manifests as mRCC. 3, 4 In particular, the introduction of targeted therapies in clinical practice has undoubtedly represented a landmark advance in the management of mRCC. 3 Regarding targeted therapies, sunitinib, pazopanib, and bevacizumab plus interferon-a are the most used and approved for the first-line setting. 4, 5 Overall, these molecules offer similar efficacy but present different safety profiles, which can help clinicians to better tailor treatment decisions.
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Pazopanib (Votrient; Novartis, Basel, Switzerland) is an orally available multietyrosine kinase inhibitor that is able to counteract angiogenesis and reduce cell growth and survival. 6 The therapeutic efficacy and safety of pazopanib in patients with mRCC were demonstrated in phase 3 randomized controlled trials versus placebo or sunitinib. [7] [8] [9] Most of the adverse events resulting from the treatment are of grade 1/2; among those with toxicity of grade 3 or higher, most frequent are diarrhea, hypertension, fatigue, and, above all, hepatic toxicity. The likelihood of developing these toxicities seems to be greater in patients with preexisting liver disease. Pazopanib is predominantly metabolized to the liver: its metabolism is primarily mediated by CYP3A4, with minor contributions by CYP1A2 and CYP2C8. 10, 11 Pazopanib is eliminated slowly, with an average half-life of 30.9 hours after receipt of the recommended dose of 800 mg. The elimination takes place mainly through feces, with renal elimination corresponding to < 4% of the administered dose. In addition to evidence from clinical trials regarding efficacy and safety, it is important to consider other factors that may influence the use of pazopanib in clinical practice. 6 For instance, patients with renal insufficiency (RI) are usually excluded from clinical trials, although their number is substantial. 12 At present limited evidence exists regarding toxicity and efficacy of targeted therapies (sunitinib, sorafenib, everolimus, temsirolimus, bevacizumab plus interferon) in these subjects; renal function has been shown to influence efficacy and safety profiles. 13, 14 To our knowledge, no study has investigated pazopanib in this population of patients. The Italian multicenter CORE-URO-01 study investigated the effect of kidney function on treatment outcomes in patients treated with pazopanib for mRCC in a clinical practice setting.
Patients and Methods

Setting and Design
This was a retrospective study conducted in 12 Italian oncologic institutions located all over the Italian territory. All the centers approved the study design, and all patients had provided written informed consent permitting the use of their personal data for research purposes.
The primary end points of the study were adverse events and toxicity profile, graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0; and progressionfree survival (PFS), defined as the time from treatment initiation to documented progression, death, or loss to follow-up, whichever occurred first. Secondary end points were clinical response and overall survival (OS), defined as the time from treatment initiation to death or loss to follow-up, whichever occurred first.
Population
The clinical records of patients diagnosed with established mRCC were treated with pazopanib as first-line therapy from January 2010 to June 2016 were reviewed. Only patients for whom data regarding renal function were available were included; no other eligibility criteria were applied. All patients were treated and managed according to the standard practice of the treating institutions.
Data Analysis
Renal function at the time of pazopanib initiation was determined on the basis of estimated glomerular filtration rate (eGFR). This parameter was calculated using the Modification of Diet in Renal Disease formula, which has been used in similar studies on other targeted therapies. 10 Patients with eGFR 60 mL/min/1.73 m 2 (poor renal function; group A) were compared to those with eGFR > 60 mL/min/1.73 m 2 (good renal function; group B). The following parameters were evaluated: clinical response, PFS, and OS. Safety considerations were also assessed, and adverse events were graded according to CTCAE version 4.0. The starting dose of pazopanib and the frequency of dose reductions were also analyzed. All data were analyzed by descriptive statistics. PFS and OS were calculated by the Kaplan-Meier method. Log-rank tests were used for comparison of PFS and OS data between the 2 patient groups. P < .05 was considered statistically significant. All analyses were performed by SPSS 22.0 software.
Results
Patients
A total of 229 patients were evaluated. Of them, 128 (56%) had poor renal function (group A) and 101 (44%) had good renal function (group B), with a median number of 16 patients for each center (range, 4-53 patients). Table 1 lists the baseline characteristics of the 2 groups. Patients were well balanced in the 2 groups, without any significant difference between groups in terms of baseline patient or disease characteristics.
In group A, the median age was 67 years (range, 34-88 years), 87 (68%) were men, and the median eGFR was 49. Table 2 summarizes information on the best response to pazopanib therapy. Disease control rate (complete response, partial response, and stable disease) was 83% in group A patients and 76% in group B patients (P ¼ .1).
Clinical Response
Survival
Overall, no significant differences in PFS were reported between the 2 groups ( Figure 1 
Toxicity
No difference between patients in groups A and B was reported in terms of globally incidence of grade 1/2 (73.3% vs. 74.2%; P ¼ .5) and grade 3/4 (23.8% vs. 32.8%; P ¼ .2) adverse events (Table 3 ). There was an increased incidence of grade 3/4 adverse events only in patients in group A aged 65 to 75 years compared to those of group B with the same age range (P ¼ .006).
Dose Reductions
In most cases, pazopanib was administered at an initial dose of 800 mg per day (group A, 102 patients, 78%; group B, 78 patients, 77%). Significantly more patients in group A (n ¼ 66; 52%) had dose reductions compared to those in group B (n ¼ 36; 36%) (P ¼ .04). First dose reduction to 600 mg was performed in 30 (45%) of 66 patients in group A and 15 (42%) of 36 in group B, and to 400 mg in 34 (52%) of 66 and 14 (39%) of 36 patients, respectively. The dose was reduced to the lowest level (200 mg) in only 2 (< 1%) of 66 and 7 (19%) and 36 of patients in groups A and B, respectively. Dose reduction was not performed for liver toxicity of grade 1/2 but only 
Discussion
Although large randomized clinical trials evaluating targeted therapies may have included a few patients with mildly impaired RI, the outcomes of this subgroup of patients have not been well characterized.
There are few data regarding safety and efficacy of the use of targeted therapies in mRCC patients with RI compared to patients with normal renal function. There have been multiple studies in the literature of patients with RI being successfully treated with these newer agents, but most of these case reports do not extensively report on the toxicities specific to targeted agents. Table 4 summarizes the published data on the use of targeted agents in mRCC with renal insufficiency but not during dialysis. In a study on 202 patients treated with sunitinib, sorafenib, or temsirolimus, subjects with eGFR < 60 mL/min/1.73 m 2 (41% of total) were more likely to experience severe treatment-induced toxicities (79% vs. 32%), but they also had longer median time 
Figure 2 Overall Survival
Abbreviations: CI ¼ confidence interval; mOS ¼ median overall survival.
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to treatment failure and OS (12 vs. 6 months and 33 vs. 13 months, respectively).
14 However, to our knowledge, evidence on the safety and efficacy of pazopanib in patients with poor renal function is scant. In this multicenter study, conducted at 12 Italian oncologic centers, we addressed this issue by evaluating a large sample of unselected patients treated in a clinical practice setting.
The median number of patients treated per center was 16; of interest, 56% of the patients in this unselected population had impaired renal function, reflecting the incidence of this condition in the real world.
Although with all the limitations of any retrospective study (eg, poor reporting), overall, we showed that kidney function at therapy initiation does not adversely affect the efficacy and safety of pazopanib. Indeed, patients with poor renal function showed a similar disease control rate, PFS, and OS compared to those with good function. Importantly, although the dose of pazopanib was reduced more frequently in patients with RI, this therapy was well tolerated in both groups, with a low rate of grade 3/4 adverse events. Nonetheless, our toxicity data are in accord with those from experiences with pazopanib use in mRCC dialysis patients. 19 In addition, no correlation between dose reduction and age ( 65 or < 65 years) was demonstrated in the 2 groups, although a higher number of patients in group A aged 65 to 75 years experienced grade 3/4 adverse events compared to those in group B, confirming that pazopanib is manageable independent of the age of the patient. The similar efficacy and safety of pazopanib in patients with poor renal function compared to those with normal function may have major relevance for therapy individualization in clinical practice. Indeed, as shown by Nouhaud et al, 14 patients with poor renal function treated with other targeted therapies may experience increased toxicity rates and lower OS compared to those without.
Conclusion
Therefore, according to our results, decreased Modification of Diet in Renal Disease was not associated with inability to receive pazopanib and did not affect the safety profile, objective response, PFS, or OS. Moreover, prospective studies may be planned that are based on our results to further confirm the efficacy and safety of pazopanib in the highly prevalent, but too often neglected, population of mRCC with poor renal function.
Clinical Practice Points
Limited data exist regarding the incidence of renal dysfunction in mRCC patients; however, this is a patient population at risk for impaired renal function. No study has specifically investigated pazopanib in this population. The Italian multicenter CORE-URO-01 study investigated the effect of kidney function on treatment outcomes in patients treated with pazopanib for mRCC in a clinical practice scenario. We retrospectively analyzed data of mRCC patients treated with pazopanib with respect to renal function. Patients with Modification of Diet in Renal Disease 60 mL/min/1.73 m 2 (group A; n ¼ 128) were compared to patients with > 60 mL/min/1.73 m 2 (group B; n ¼ 101) in terms of PFS, toxicities, response rates, and OS. Median PFS was 14 months (95% CI, 9.4-18.5) and 17 months (95% CI, 11.4-22.8), and OS was 30.5 months (95% CI 8-53) and 41.4 months (95% CI 21-62) for group A and group B, respectively, with no statistically significant difference (P ¼ .6).
No difference between the 2 groups was reported in the incidence of adverse events. Decreased Modification of Diet in Renal Disease score is not associated with inability to receive pazopanib and does not affect safety profile, objective response, PFS, or OS. Moreover, on this basis, prospective studies may be planned to further confirm the efficacy and safety of pazopanib in the highly prevalent-but too often neglected-population of patients with mRCC with poor renal function.
